Intelligent Pharmacy Bureau learned that on October 23, Ensem Therapeutics (hereinafter referred to as "ENSEM") announced the completionNearly $10 Million A+ Round Financing。This round of investment includes Legend Star, Boquan Capital, MegaTech, etc. The funds raised will continue to be used for its uniqueAI Platform Kinetic Ensemble® Development Optimization and Pipeline Advancement.
April 6 last year,ENSEMCompleted a $67 million Series A financing round,By Yori SourceCo-led by Ben and Alibaba。The founder is of Chinese descent and has led the launch of FIC innovative drugs.
ENSEM TherapeuticsAsian Asset Management Company CBC GroupIncubated in 2021, headquartered in Boston, USA, founded by Shengfang Jin.Jin Shengfang graduated from Wuhan University with a bachelor's degree and obtained her Ph.D. from Tufts University School of Medicine in the United States. She also completed postdoctoral training in oncology and tumor immunology at Harvard Medical School.After graduation, she has been working in the pharmaceutical industry for a long time, and has alreadyOver 25 YearsExperience in the research and development of treatments for tumors and rare genetic diseases.She also once led the Nasdaq-listed company Agios Pharmaceuticals' team to successfully develop a First-In-Class innovative drug.IDHIFA、TIBSOVO、PYRUKYND, and received FDA approval for marketing.In addition, ENSEM has gathered the world's top scientists in the fields of AI, technology, life sciences, and pharmaceuticals. With CBC’s unique "investment plus operation" strategic model and extensive entrepreneurial experience in healthcare enterprises, they are accelerating the exploration of innovative drug R&D technology platforms.Since its establishment, ENSEM has successfully predicted dynamic pockets that have never been discovered in the industry and can significantly impact the activity and selectivity of drug molecules by applying state-of-the-art industrial deep learning models in the pharmaceutical field to research globally recognized difficult oncology drug targets.At the same time, based on this dynamic pocket, ENSEM has developed the world's Best-In-Class small molecule candidate drug, which has now officially entered the PCC preclinical IND-Enabling trial stage.Comparison with U.S. Big Pharma Competitors, ENSEM Therapeutics conducted head-to-head comparisons through preclinical in vitro, in vivo, and toxicology experiments. The ENSEM PCC molecule showed significant improvements in activity, selectivity, drug-like properties, and therapeutic window, thereby addressing issues such as poor drug-like properties and off-target effects of competing molecules.Regarding this round of financing, Jin Shengfang stated: "ENSEM was founded in the Alphafold2 era, and its cutting-edge technology can facilitate drug discovery for 'difficult-to-drug targets.' In the future, on the platform side, the company will continue to collaborate with industry shareholders for iterative improvements; in terms of pharmaceuticals, the company will remain committed to developing drug molecules with significant medical value, thereby benefiting more patients."
AI Platform Empowers Efficiently, Multiple Pipelines Enter Clinical StageThe core business of ENSEM is to utilize its unique Kinetic Ensemble® platform, combining computational and artificial intelligence deep learning methods with advanced experimental techniques,Discovery of hidden binding sites in traditionally difficult drug targets, thereby accelerating structure-based drug design.The platform can simulate the dynamic changes of proteins under different conditions, identify structural changes that small molecule drugs can induce or stabilize, and optimize candidate drugs through high-throughput screening and validation.It is characterized by high efficiency, flexibility, and innovation, capable of addressing complex and variable tumor targets, offering new opportunities for precision medicine.
Source: ENSEM official websiteAt this stage, ENSEM Therapeutics, Inc. already has candidate drugs targeting multiple tumor targets, includingKRAS、MYC、BET, some of which have entered the preclinical or clinical stage.In the next few years, ENSEM Therapeutics plans to bring more drugs into clinical trials, providing cancer patients with additional treatment options.In addition, ENSEM will also use this round of financing to expand its business scope and explore the application of AI in other disease fields, such as genetic diseases, neurodegenerative diseases, etc.Wang Feng, founding partner of Legend Star, Chen Xiaodong, founding partner of Boquan Capital, and Li Mingbo, founder and CEO of Magnesium Robotics, have all expressed optimism about Ensem Therapeutics. Its top-tier team, leading AI platform, and robust pipeline are expected to develop groundbreaking and transformative new drugs in the field of oncology.
